Modern approaches to risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy

Close metadata

Recommended articles:

History of diagnosis and treatment of hypertrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(6):634-641

Features of left ventricular outflow obstruction in patients with different phenotypes of hypertrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):7-13

Mitral valve disjunction in patients with myxomatous degeneration and severe mitral regurgitation. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(1):102-106

Repeated reconstructive interventions after septal myectomy for persistent left ventricular outflow tract obstruction and/or mitral insufficiency. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):119-124

The STADHIS stratification scale for evaluating the mortality risk in patients with acute limb ischemia following embolism. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):176-183

Surgical treatment of mid-ventricular hypertrophic obstructive cardiomyopathy with apical aneurysm. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):545-549

Rare mutations V453X and Y847X in MYBPC3 gene do not lead to severe form of hypertrophic cardiomyopathy in Russian population. Molecular Genetics, Microbiology and Virology. 2023;(4):10-14

Prediction of ventricular tachyarrhythmias by using of remote monitoring system for implantable cardioverter-defibrillators. Russian Cardiology Bulletin. 2024;(1):47-55

The algorithm for morphological assessment of malignant potential of adrenocortical tumors using mathematical modeling method. Russian Journal of Archive of Pathology. 2024;(3):21-29

Incidence of sudden cardiac death among diseases of the circulatory system during the COVID-19 pandemic in the Penza region. Forensic Medical Expertise. 2024;(5):10-14

Keywords:

hypertrophic cardiomyopathy

sudden cardiac death

risk stratification

mutations

Authors:

Khabarova N.V.

Nauchno-issledovatel'skiĭ otdel NOK tsentra "Metabolicheskiĭ sindrom" NITs GBOU VPO Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii

List of references:

Belenkov YU.N., Privalova E.V., Kaplunova V.YU. Gipertroficheskaya kardiomiopatiya [Hypertrophic cardiomiopathy]. M: GEHOTАR 2011. (in Russian)
Karpov R.S., Puzyrev K.V., Pavlyukova E.N., Stepanov V.А. Molekulyarno-geneticheskij analiz gipertrofii miokarda levogo zheludochka [Molecular genetic analysis of left ventricular hypertrophy]. Kardiologiya 2001; 6: 25-30. (in Russian)
Kiselev I.O., Fedorov V.V., SHlyakhto E.V. Molekulyarno-geneticheskie mekhanizmy razvitiya gipertroficheskoj kardiomiopatii [Molecular and genetic mechanisms of hypertrophic cardiomyopathy]. Аrterial'naya gipertenziya 2000; 6: 44-51. (in Russian)
ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation 2011; 124: 783-831.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophyc Cardiomyopathy. Eur Heart J 2003; 24: 1965-1991.
Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in Hypertrophic cardiomiopathy. J Am Coll Cardiol 2005; 45: 697-704.
Adabag A.S., Maron B.J., Appelbaum E. et al. Occurence and freqency of arrhytmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008; 51: 1369-1374.
Anan R., Greve G., Thierfelder L. et al. Prognostic implications of novel beta myosin heavy chain gene mutation that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93: 280-285.
Bos J.M., Maron B.J., Ackerman M.J. et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in Hypertrophic cardiomiopathy. Am J Cardiol 2010; 106: 1481-1486.
Cannan C.R., Reeder G.S., Bailey K.R. et al. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation 1995; 92: 2488-2495.
Cecchi F., Maron B.J., Epstein S.E. Long-term outcome of patients with hyperthrophic cardiomiopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989; 13: 1283-1288.
Cecci F., Olivotto I., Montereggi A. et al. Hypertropyic Cardiomyopathy in Tuscany: clinical course and outcome in unselected regional population. J Am Coll Cardiol 1995; 26: 1529-1536.
Cecchi F., Olivotto I., Montereggi A. et al. Prognostic value of nonsustained ventricular tachycardia and the potential role of amiodarone treatment in Hypertrophic cardiomiopathy. Heart 1998; 79: 331-336.
Charron P., Dubourg O., Desnos M. et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophyc cardiomyopathy in a genotyped adult population. Circulation 1997; 96: 1: 214-219.
Elliott P.M., Gimeno J.R., Mahon N.G. et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with Hypertrophic cardiomiopathy. Lancet 2001; 357: 420-424.
Elliott P.M., Gimeno J.R., Tome M.T. et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933-1941.
Elliott P.M., Poloniecki J., Dickie S. et al. Sudden death in Hypertrophic cardiomiopathy: identification of high risk patients. J Am Coll Cardiol 2000; 36: 2212-2218.
Elliott P.M., Sharma S., Varnava A. et al. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 1596-1601.
Fananaparzir L., Chang A.C., Epstein S.E. et al. Prognostic determinants in hypertrophic cardiomyopathy: prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation 1992; 86: 730-740.
Geske J.B., Sorajja P., Ommen S.R. et al. Left ventricular outflow tract gradient variability in Hypertrophic cardiomyopathy. Clin Cardiol 2009; 32: 397-402.
Gimeno J.R., Tome-Esteban M., Lofiego C. et al. Exercise-induced ventricular arrhytmias and risk of sudden cardiac death in patients with Hypertrophic cardiomiopathy. Eur Heart J 2009; 30: 2599-2605.
Harris K.M., Spirito P., Maron M.S. et al. Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114: 216-225.
Kisilbash A.M., Heinle S.K., Grayburn P.A. Spontaneous variability of left ventricular outflow tract gradient in hyperthropic obstructive cardiomyopathy. Circulation 1998; 97: 461-466.
Maki S., Ikeda H., Muro A. et al. Predictors of sudden cardiac death in Hypertrophic cardiomiopathy. Am J Cardiol 1998; 82: 774-778.
Marian A.J., Roberts R. Molecular genetic basis of Hypertrophic cardiomiopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998; 9: 88-99.
Maron B.J. Hypertrophyc cardiomyopathy: a systematic review. JAMA 2002; 287: 1308-1320.
Maron B.J. Sudden death in young athletes. N Engl J Med 2003; 349: 1064-1075.
Maron B.J. Contemporary insights and strategies for risk stratification and prevention of sudden death in Hypertrophic cardiomiopathy. Circulation 2010; 121: 445-456.
Maron B.J., Casey S.A., Poliac L.C. et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
Maron B.J., Doerer J.J., Haas T.S. et al. Sudden death in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009; 119: 1085-1092.
Maron B.J., Gardin J.M., Flack J.M. et al. Prevalence of Hypertrophic cardiomiopathy a general population of young adults: Echocardiographic analisysis of 4111 subjects in the CARDIA study. Circulation 1995; 92: 785-789.
Maron B.J., Haas T.S., Shannon K.M. et al. Long-term survival after cardiac arrest in Hypertrophic cardiomiopathy. Heart Rhythm 2009; 6: 993-997.
Maron B.J., McKenna W.J., Danielson G.K. et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on Hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713.
Maron B.J., Olivotto I., Spirito P. et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patients population. Circulation 2000; 102: 858-864.
Maron B.J., Savage D.D., Wolfson J.K. et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertropic cardiomiopathy: a prospective study. Am J Cardiol 1981; 48: 252-257.
Maron B.J., Semsarian C., Shen W.K. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with Hypertrophic cardiomiopathy. Heart Rhythm 2009; 6: 599-602.
Maron B.J., Shen W.K., Link M.S. et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with Hypertrophic cardiomiopathy. N Engl J Med 2000; 342: 356-373.
Maron B.J., Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomiopathy. J Cardiovasc Electrophysiol 2008; 19: 1118-1126.
Maron B.J., Spirito P., Shen W.K. et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in Hypertrophic cardiomiopathy. JAMA 2007; 298: 405-412.
Maron M.S., Appelbaum E., Harrigan C.J. et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008; 1: 184-191.
Maron M.S., Finley J.J., Bos J.M. et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in Hypertrophic cardiomiopathy. Circulation 2008; 118: 1541-1549.
Maron M.S., Olivotto I., Betocchi S. Effect of left ventricular outflow tract obstruction on clinical outcome in hepertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
McKenna W., Deanfield J., Faruqui A. et al. Prognosis in Hypertrophic cardiomiopathy: role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
McLeod C.J., Ommen S.R., Ackerman M.J. et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive Hypertrophic cardiomyopathy. Eur Heart J 2007; 28: 2583-2588.
Moolman J.C., Corfield V.A., Posen B. et al. Sudden death due to troponin T mutation. J Am Coll Cardiol 1997; 29: 549-555.
Moon J.C., McKenna W.J., McCrohon J.A. et al. Toward clinical risk assessment in Hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-1567.
Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.
O'Hanlon R., Grasso A., Roughton M. et al. Prognostic significance of myocardial fibrosis in Hypertrophic cardiomiopathy. J Am Coll Cardiol 2010; 56: 876-874.
Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of Hypertrophic cardiomiopathy. Circulation 2001; 104: 2517-2524.
Olivotto I., Gistri R., Petrone P. et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315-321.
Olivotto I., Maron B.J., Montereggi A. et al. Prognostic value of systemic blood pressure response during exercise in a community-based patients population with Hypertrophic cardiomiopathy. J Am Coll Cardiol 1999; 33: 2044-2051.
Ommen S.R., Maron B.J., Olivotto I. et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomiopathy. J Am Coll Cardiol 2005; 46: 470-476.
Rubinshtein R., Glockner J.F., Ommen S.R. et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced MRI in patients with Hypertrophic cardiomiopathy. Circ Heart Fail 2010; 3: 51-58.
Sadoul N., Prasad K., Elliott P.M. et al. Prospective prognostic assesment of blood pressure response during exercise in patients with Hypertrophic cardiomiopathy. Circulation 1997; 96: 2987-2991.
Semsarian C., Yu B., Ryce C. et al. Sudden cardiac death in familial Hypertrophic cardiomiopathy: are "benign" mutation really benign? Pathology 1997; 29: 305-308.
Sorajja P., Nishimura R.A., Ommen S.R. et al. Use of echocardiography in patients with Hypertrophic cardiomiopathy: clinical implications of massive hypertrophy. J Am Soc Echocardiogr 2006; 19: 6: 788-795.
Spirito P., Autore C., Rapezzi C. et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703-1710.
Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular Hypertrophy and risk of sudden death in Hypertrophic cardiomiopathy. N Engl J Med 2000; 342: 1778-1785.
Spirito P., Chiarella F., Carratino L. et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population. N Engl J Med 1989; 320: 749-755.
Spirito P., Rapezzi C., Autore C. et al. Prognosis of asymptomatic patients with hypertrophic cardiomiopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-2747.
Van Driest S.L., Ackerman M.J., Ommen S.R. et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in Hypertrophic cardiomiopathy. Circulation 2002; 106: 3085-3090.
Van Driest S.L., Maron B.J., Ackerman M.J. From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing Hypertrophic cardiomiopathy. Heart 2004; 90: 7-8.
Watkins H., Rosenzweig A., Hwang D.S. et al. Characteristics and prognostic implications of myosin missense mutations in familial Hypertrophic cardiomiopathy. N Engl J Med 1992; 326: 1108-1114.

Close metadata